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Abstract 
 
Objective: To investigate the utility of HPV DNA testing and p16/Ki-67 dual 
staining for detecting CIN2+ and CIN3 in women referred to colposcopy with minor 
abnormal cervical cytology LSIL and AS-CUS. The clinical performance of both 
tests was evaluated as standalone tests and combined tests, for detection CIN2+ 
and CIN3 over 2 years. 
 
Methods: ThinPrep® liquid based cytology specimens were collected from 1349 
women with repeat LSIL or ASC-US. HPV DNA was performed using Hybrid 
Capture. Where adequate material remained (n=471), p16/Ki-67 over expression 
was assessed. The clinical performance for detection of histologically diagnosed 
CIN2+ and CIN3, was calculated for both tests. 
 
Results: Overall 62.2% of the population were positive for HPV DNA, and 30.4% 
were positive for p16/Ki-67. p16/Ki-67 showed no significant difference in 
positivity between LSIL and ASC-US referred patients (34.3% vs 28.6%; 
p=0.189). Women under 30 years had a higher rate of p16/Ki-67 positivity 
compared to those over 30 years (36.0% vs 26.6%; p=0.03). Overall HPV DNA 
testing produced a high sensitivity for detection of CIN3 of 95.8% compared to 
79.2% for p16/Ki-67. In contrast, p16/Ki-67 expression offered a higher 
specificity, 75.2% versus 40.4% for detection of CIN3. Combining p16/Ki-67 with 
HPV DNA testing improved accuracy in distinguishing between CIN3 and <CIN3. 
The absolute risk of CIN3 increased from 15.6% in women who were HPV DNA 
positive to 27% in women positive for HPV DNA and p16/Ki-67. Those negative 
for HPV DNA and p16/Ki-67 had a low risk of 1.2%, of CIN3. 
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Conclusion: The addition p16/Ki-67 to HPV DNA testing lead to a more accurate 
stratification of CIN in women presenting with minor cytological abnormalities. 
 
Key words: Human Papillomavirus, p16/Ki-67, Triage, Low grade squamous 
intraepithelial lesion, Atypical squamous cells of undetermined significance 
 
Introduction 
Based on the known causal relationship between high risk human papillomavirus 
(HR HPV) and cervical cancer (1), HPV testing has become an important tool in 
developing strategies for cervical cancer screening. It was initially approved as a 
triage test for minor cytological abnormalities, providing improved detection of 
cervical intraepithelial grade 2 or worse (CIN2+) compared with repeat cytology 
(2-4). However, despite the utility of HPV testing in triage, concern remains over 
the reported suboptimal specificity of HPV DNA based tests (5). This is due to the 
fact that HPV DNA testing cannot discriminate transforming infections from 
transient infections of minor clinical relevance. Knowledge of HPV pathophysiology 
has enabled the identification of a number of biomarkers with potential to 
distinguish those at risk of disease progression. Several host cell biomarkers have 
been evaluated for their potential to improve the diagnostic specificity of cervical 
screening (6). One of the most promising cellular protein markers to be identified 
is the cyclin dependent kinase inhibitor p16INK4A (referred to as p16 hereafter) (7-
9). However, p16 can be over expressed in some non-dyskaryotic cells (10) and, 
as a consequence, morphological criteria are needed (11). It is known that 
increased expression of p16 signals functional activation of E2F mediated by HPV 
E7. Combining p16 with the proliferation marker Ki-67 signals HPV transformed 
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cells undergoing proliferation. Studies have reported on the clinical performance 
of dual staining for p16 and Ki-67 for detection of CIN2+ and CIN3 (13-19). 
However, longitudinal data is limited on its utility as a triage tool for minor 
cytological abnormalities LSIL (low grade squamous intraepithelial lesion) and 
ASC-US (atypical cells of undetermined significance). 
 
The purpose of this two year prospective study was to examine two testing 
modalities, HPV DNA and p16-Ki-67, with an aim to identify an approach to best 
manage women with LSIL and ASCUS on cytology.  
 
Materials and Methods 
Study population 
The study setting was Ireland. At commencement of the study guidelines from 
CervicalCheck, the National Cervical Screening Program, state the following for 
referral to colposcopy following minor cytological abnormalities on ThinPrep® 
liquid based cytology: 1.) three consecutive ASC-US; 2.) two consecutive LSIL; 
3.) two consecutive cytology samples graded a combination of ASC-US and LSIL; 
or 4.) having any three ThinPrep® liquid based cytology test results that are not 
normal in the previous 10 years without referral to colposcopy (12). Women gave 
written informed consent to take part in the study at their first visit to colposcopy 
following referral for repeat LSIL and ASC-US cytology at the National Maternity 
Hospital, Holles Street, Dublin from October 2008 to July 2011. Women were 
excluded from the study if they were pregnant, under the age of 18 or had been 
treated for CIN in the previous 5 years. All women were assessed by BSCCP 
(British Society for Colposcopy and Cervical Pathology) trained colposcopists. 
Women were followed over the period of time they spend under surveillance where 
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they were managed according to the standard protocol of the clinic. This involved 
follow up by 6 month cytology following the initial colposcopy visit. If a high grade 
lesion was identified at the initial colposcopy or during follow up, women were 
brought back within a shorter period, for repeat colposcopy and treatment. 
Women with persistent minor abnormalities identified at their initial colposcopy 
(Time 0 months) and up to three or more subsequent follow up visits (time 18 
months), were offered treatment. Women were followed over a two year period 
or until they reached defined study endpoints. Study endpoints included having 
two consecutive normal cytology results and discharge from the clinic without 
treatment, or alternatively, having a LLETZ (Large Loop Excision of the 
Transformation Zone). The majority of women, 90.7% (427/471), had a histologic 
diagnosis over the two year follow up period by punch biopsy and/or LLETZ. 
Histological diagnosis was based on a standard protocol outlined in the 
CervicalCheck guidelines. In this study CIN was diagnosed by a pathologist in daily 
routine practice to allow test performance to be evaluated in a routine population- 
based setting. All results were collected and recorded from the participating 
hospital. The study was approved by The Research Ethics Committee at the 
National Maternity Hospital, Holles Street, Dublin. 
 
HPV DNA testing 
A ThinPrep® liquid based cytology specimen was taken for HPV testing and 
immunocytochemistry (ICC) prior to first colposcopic examination. Detection of 
DNA from oncogenic HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 
68 was performed using Hybrid Capture 2 (HC2) (Qiagen, GmbH, Hilden, 
Germany), as described by the manufacturer. The RLU/CO negative cut off value 
was 1.0. Specimens below this detection limit were considered negative. 
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p16/Ki-67 dual stain 
Cytology slides from residual ThinPrep® material, from the same sample used for 
HPV testing, were prepared using a T2000 slide processor. The CINtec PLUS® kit 
(Roche mtm Laboratories AG, Mannheim, Germany) was used for ICC staining of 
p16 and Ki-67 in accordance with the manufacturer’s instructions. A positive result 
was interpreted as brown cytoplasmic staining for p16 expression and red nuclear 
staining for Ki-67 expression. The presence of one or more stained epithelial cells, 
showing simultaneous expression, signified a positive result. All cases were 
subjected to a pathologist review, blinded to histology and HPV status. All testing 
on ThinPrep® Specimens was performed within three months of obtaining the 
specimen. Results from HPV testing and ICC were not disclosed to the participants 
or used for patient management. 
 
Statistical Analysis 
The final outcome was based on the histological grade taken as the worse of the 
histological findings on punch biopsy or LLETZ during a patient’s time at 
colposcopy. The primary disease endpoint was histologically confirmed CIN2+ 
and CIN3, diagnosed within two years of the first colposcopy visit. While staining 
for p16 has been recommended to improve diagnosis of CIN2 (20) it was not 
possible for this study. We included CIN3 as a clinical endpoint as it is considered 
the true pre-cursor to cervical cancer. Women who had a normal colposcopy, 
without biopsy, at initial or follow up visits were classified as <CIN2/3. Data was 
analysed using Minitab statistical software version 16. Confidence intervals were 
calculated where appropriate. McNemar’s test was used to compare differences 
in disease detection between HPV DNA and p16/Ki-67. A p value <0.05 was 
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considered statistically significant. The clinical performance of both tests, HPV 
DNA and p16/Ki-67, was assessed by calculating the sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), and the relative 
95% confidence intervals (CI) for detecting CIN2+ and CIN3 over a two year 
follow up period in those with a histological diagnosis only. Additional sensitivity, 
specificity, PPV and NPV were calculated stratified by age and referral cytology. 
 
Results 
Among the 1346 women recruited in to the study, 1079 had a complete HPV DNA 
result. Of the 1079, 764 had residual material available to prepare a ThinPrep® 
slide. As additional tests, not included in this analysis, were performed on the 
same samples cellularity was low in some cases and resulted in exclusion of a 
further 293 cases. The final study population was 471. All subsequent results are 
based on this group of 471 women.  
 
The median age of the population at enrolment was 31 years (interquartile range 
27-38). LSIL referral was more common representing 56.3% (265/471) of 
referrals compared to ASC-US at 43.7% (206/471). Within a two year period, 
29.3% (138/471) of women had a CIN2+ diagnosis on histology, 65.2% (90/138) 
of whom were classified as CIN2 and 34.8% (48/138) classified as CIN3. The 
majority, 83.3% (115/133), of CIN2+ was identified on histology at the first visit, 
generally following punch biopsy. The remaining 18 cases were identified at follow 
up visits (Figure 1A). Figure 1B illustrates the time at which treatment occurred 
for high grade CIN. Within the two year follow up period, a total of 33.1% 
(156/471) of women received a LLETZ treatment, 87.2% (136/156) to treat a 
suspected high grade lesion and 12.8% (20/156) for a persistent low grade lesion. 
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Two out of twenty women treated for a persistent low grade lesion had CIN2 on 
their LLETZ specimen. In total 22.7% (107/471) of women remained under 
surveillance after two years follow up. The majority of women who remained under 
surveillance, 85.0% (91/107), were under the age of 40 years. A further 44.2% 
(208/471) of the overall population exited the study having had two sequential 
normal cytology results and no treatment.  
 
The prevalence of p16/Ki-67 and HPV DNA at recruitment indicated p16/Ki-67 
over-expression was present in 30.4% (95% CI 28.5-32.3) of women, compared 
with a HPV DNA prevalence rate of 62.2% (95% CI 60.1-64.3). p16/Ki-67 was 
positive in 34.3% of women referred with LSIL and 28.6% (59/206) referred with 
ASCUS (p=0.189). HPV DNA was positive in 71.7% (190/265) of LSIL referrals 
and 50.5% of ASCUS referrals (p<0.001). The prevalence across each grade of 
CIN is shown in table 1. HPV DNA testing detected a higher proportion of CIN2+ 
and CIN3, compared to p16/Ki-67 testing (p<0.001). However, a positive HPV 
DNA result identified over twice as many women (57.9% and 84.4%) as p16/Ki-
67 (27.8% and 73.2%) who, in fact, had no CIN2+ or CIN3 including women with 
persistent low grade abnormalities and those discharged with two sequential 
normal cytology results (table 1).  
 
Table 2 shows, separately, the clinical performance characteristics of p16/Ki-67 
and HPV DNA testing for detection of CIN2+ and CIN3. The calculations are based 
on those with a histological diagnosis over two years (n=427). HPV DNA detection 
demonstrated the highest sensitivity, 92.8% and 95.8%, but with limited 
specificity 48.9% and 40.4% for CIN2+ and CIN3 respectively. In comparison 
p16/Ki-67 had a lower sensitivity of 75.4% and 79.2%, and higher specificity of 
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88.3% and 75.2% for CIN2+ and CIN3. p16/Ki-67 demonstrated a significantly 
higher PPV of 26.6%, for detection of CIN3, compared to 15.4% for the HPV DNA 
test (p<0.001). Whereas HPV DNA testing had a significantly higher NPV of 
98.8%, compared to p16/Ki-67 at 97.0% (p=0.01). p16/Ki-67 testing showed 
comparable sensitivity and specificity in both LSIL and ASC-US referrals, whereas 
HPV DNA testing had significantly higher sensitivity and specificity in ASC-US 
compared to LSIL. Table 3 contains the clinical performance, stratified by age. 
p16/Ki-67 was positive in 36.0% of women under 30 years and 26.6% of women 
over 30 years (p=0.029). HPV DNA was positive in 70.9% of women under 30 
years and 58.2% of women over 30 years (p=0.006). Both tests demonstrated a 
similar sensitivity across both age groups but specificity increased in women aged 
30 years and older for each test.  
 
From the overall population 62.2% were positive for HPV DNA, 41.6% of whom 
had CIN2+ and 15.6% had CIN3 over the study period. There were 30.4% with a 
positive p16/Ki-67 result, 72.0% had a CIN2+ and 27.3% had a CIN3 diagnosis. 
Clinical outcome following combined testing of p16/Ki-67 and HPV DNA, is shown 
in figure 2. From the general population of 471 women, 29.5% had a double 
positive test result; 74.1% of these women had CIN2+ and 27.3% had CIN3 
diagnosed. Over two years, the absolute risk of CIN2+ and CIN3 was 15% and 
6.3% in women with a positive HPV result and a negative p16/Ki-67 result. The 
absolute risk of CIN2+ was 5.4% and CIN3 was 1.2% in women with a negative 
HPV DNA and negative p16/Ki-67 result. 
 
Discussion 
Minor abnormalities, LSIL and ASC-US, represent a large burden at colposcopy. A 
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large proportion of these will not lead to a diagnosis of CIN2+ or CIN3 yet still 
remain under extensive follow up. Efforts have been made to manage this by 
introducing HPV DNA triage of minor abnormal cytology. However, due to the low 
specificity, HPV DNA testing can still lead to over- referral to colposcopy. In this 
study we investigated potential options for triaging women attending colposcopy 
following repeat minor abnormal cytology. We found from a population of women 
attending colposcopy with LSIL and ASCUS on cytology only 29.3% and 10.2% 
had underlying or subsequent CIN2+ and CIN3 lesions over two years. We have 
shown that a combined HPV DNA and p16/Ki-67 testing approach could be a 
potential tool for predicting diagnosis of CIN2+ and CIN3 in these women.  
 
The two triage modalities, p16/Ki-67 and HPV DNA, were initially explored as 
standalone tests. HPV DNA was over three times higher than p16/Ki-67 in women 
with persistent low grade lesions and those discharged with no CIN. Unlike HPV 
DNA testing, there was no significant difference in the proportion of women with 
p16/Ki-67 co-expression between LSIL and ASC-US referred patients, an 
important finding considering the reported limited use of HPV DNA triage in LSIL 
(2,3). Furthermore p16/Ki-67 showed only a modest difference in performance 
with respect to age of women compared to HPV testing, which showed a 
substantially reduced specificity in women under the age of 30 years. On the other 
hand, compared to p16/Ki-67, HPV DNA was positive in a significantly higher 
proportion of CIN2+ and CIN3 (p<0.001). This highlights the lower sensitivity of 
p16/Ki-67 compared to HPV DNA testing. Although, sensitivity for p16/Ki-67 in 
the current study is similar to previous studies (13-19). Generally PPV appeared 
low, this is due to the low prevalence of CIN3 in this population, 10%, and is in 
line with other studies showing a similar prevalence of CIN3 (14, 15, 18). Overall 
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specificity and PPV demonstrated by p16/Ki-67 remained higher than that 
demonstrated by HPV DNA across all categories. However as HPV DNA testing 
outperformed with respect to sensitivity and NPV we investigated a combined 
testing approach in order to maintain the high sensitivity of HPV testing and 
improve specificity with p16/Ki-67.  
 
When combined, 29.5% were found to be positive for both tests, from these 
74.1% had CIN2+ and 27.3% CIN3 diagnosed. Combined testing presented the 
most efficient option for identifying CIN2+ and CIN3 in women with repeat minor 
abnormal cytology as it identified almost one third of the population as requiring 
immediate colposcopy, signified by a double positive result. A negative p16/Ki-67 
and negative HPV DNA maintained a high level of reassurance against CIN3 
(1.2%) similar to that of a negative HPV test alone. A risk of CIN3 <2% has been 
previously deemed safe to allow return to routine recall (20). An important 
consideration in the use of a combined testing approach is how to manage women 
with discordant results, i.e. who are HPV positive p16/Ki-67 negative. Due to the 
risk of CIN2+ and CIN3 in these individuals it would probably be best advised that 
they do not return to routine recall but have some form of follow-up or colposcopy 
referral. An approach of repeat HPV testing of women who are HPV positive 
cytology negative after one year has been previously recommended (21).  
 
The strengths of this study are that enrolment was systematic through the Irish 
national screening program, CervicalCheck. Women were managed under a 
standard protocol outlined by CervicalCheck guidelines. These attributes allowed 
test performance to be evaluated in a routine population-based setting. The 
consequence of this real-world setting was, however, that some women were not 
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managed according to the protocol, but this probably reflects the day-to-day 
reality of colposcopy clinics. A limitation of this study it that it focused on a 
population of women attending colposcopy on the bases of repeat minor cytology 
rather than a single ASC-US or LSIL, which a secondary test would be applied. 
However, sensitivity in the current study remains consistent with previous studies 
(13-19). While a large number of samples were excluded based on low cellularity 
this is likely due to the fact two or more tests were performed on the samples 
prior to the ThinPrep® slide been made. In reality a triage test would be performed 
following only one HPV test, as such we do not anticipate cellularity to be an issue.  
 
While this work has established that HPV DNA and p16/Ki-67 may play a role in 
cervical screening programmes, large studies with long term follow up are 
warranted in order to determine an optimal management algorithm. Management 
of HPV DNA positive p16/Ki-67 negative women will need to be addressed in order 
to predict the intervals for retesting and return to routine screening. Moreover, 
further studies investigating triage following an initial minor cytological 
abnormality and in the context of primary screening with HPV will be important. 
Currently triage of primary screened HPV positive women by cytology is 
recommended however a question still remains over how to manage HPV positive 
cytology negative women. Dual staining for p16/Ki-67 has been previously shown 
to help further stratify Pap negative/HPV positive women that at a highest risk of 
underlying high-grade disease (19). In addition, cost-effective analysis will be an 
important aspect to help provide guidelines on the delivery and implementation in 
of such models in cervical screening. While other studies have found p16/Ki-67 
superior to HPV E6/E7 mRNA testing by the APTIMA HPV assay (18), further 
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studies on the role of the ATPIMA assay in combination with p16/Ki-67, in addition 
to number of positive cells and morphology should be explored.  
 
In conclusion, we have shown that combining HPV DNA positive women with 
p16/Ki-67 testing could lead to more accurate stratification of CIN in women 
presenting with minor cytology, potentially reducing referrals to colposcopy. This 
strategy is worthy of further evaluation in terms of both clinical-effectiveness and 
cost-effectiveness. While adding an additional test to screening may be more 
costly, introducing further stratification of minor abnormalities, prior to colposcopy 
rather than at colposcopy, should reduce unnecessary work up and treatment. 
This will benefit women by reducing the psychosocial effects endured from having 
repeat abnormal smears and attending colposcopy clinics, in addition to reducing 
cost associated with colposcopy visits (22).  
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